Working… Menu

AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00303862
Recruitment Status : Terminated
First Posted : March 17, 2006
Results First Posted : November 20, 2013
Last Update Posted : May 21, 2014
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase II trial is studying how well AZD2171 works in treating patients with refractory metastatic kidney cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Condition or disease Intervention/treatment Phase
Clear Cell Renal Cell Carcinoma Recurrent Renal Cell Cancer Stage IV Renal Cell Cancer Drug: cediranib maleate Other: laboratory biomarker analysis Phase 2

Detailed Description:


I. Determine the objective response rate in patients with refractory metastatic renal cell carcinoma treated with AZD2171.


I. Determine the safety and tolerability of AZD2171 in these patients. II. Determine the feasibility of performing standardized delayed contrast-enhancement-MRI correlative studies across different institutions and platforms with data-sharing capability in patients with metastatic renal cell cancer.

III. Generate preliminary data regarding potential utility of pharmacogenomic and plasma/serum biomarkers of angiogenesis as predictive or prognostic markers for future investigations of AZD2171 and renal cell carcinoma.

OUTLINE: This is a multicenter study.

Patients receive oral AZD2171 once daily for 4 weeks. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for 6 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of AZD2171 in Patients With Advanced Renal Cell Carcinoma
Study Start Date : March 2006
Actual Primary Completion Date : March 2011
Actual Study Completion Date : March 2011

Arm Intervention/treatment
Experimental: Treatment (cediranib maleate)
Patients receive oral AZD2171 once daily for 4 weeks. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
Drug: cediranib maleate
Given orally
Other Names:
  • AZD2171
  • Recentin

Other: laboratory biomarker analysis
Correlative studies

Primary Outcome Measures :
  1. Objective Response [ Time Frame: Up to 6 weeks ]
    Objective radiologic response as measured by RECIST criteria. (30% or greater shrinkage in the sum of the longest diameters of target lesions)

Secondary Outcome Measures :
  1. Performance of DCE_MRI [ Time Frame: One month after initiating therapy ]
    Binary (yes/no) indicator of whether a dynamic contrast-enhanced MRI (DCE-MRI)was successfully performed.

  2. KDR [ Time Frame: Day 28 after initiation of therapy ]
    Kinase insert domain-containing vascular endothelial growth factor receptor

  3. eNOS [ Time Frame: Baseline (prior to therapy) ]
    Endothelial nitric oxide synthase gene (eNOS). Record genotype=number of minor alleles.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed clear cell renal cell cancer

    • Must be predominantly metastatic disease
    • Refractory disease
  • Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mmby conventional techniques or ≥ 10 mm by spiral CT scan
  • No known brain metastases
  • ECOG performance status 0-2
  • Karnofsky 60-100%
  • WBC ≥ 3,000/mm^3
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 8.0 g/dL
  • AST and ALT ≤ 2.5 times upper limit of normal (ULN)
  • Bilirubin normal
  • Creatinine normal OR creatinine clearance > 60 mL/min
  • Blood pressure < 140/90 mm Hg on 2 separate occasions not more than 6 weeks prior to enrollment and not less than 24 hours apart (stable antihypertensive regimen allowed)
  • Mean QTc ≤ 470 msec (with Bazett's correction)
  • Less than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No history of familial long QT syndrome
  • No cardiac arrhythmia
  • No unstable angina pectoris
  • No symptomatic congestive heart failure
  • No New York Heart Association class III or IV disease
  • No ongoing or active infection
  • No hypertension
  • No other uncontrolled intercurrent illness
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD2171
  • No psychiatric illness or social situations that would limit compliance with study requirements
  • See Disease Characteristics
  • More than 4 weeks since prior radiotherapy and recovered
  • More than 4 weeks since prior major surgery and recovered
  • More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered
  • More than 30 days since other prior investigational agents
  • No prior therapy with vascular endothelial growth factor (VEGF) binding agents or VEGF receptor (VEGFR) tyrosine kinase inhibitors
  • No more than 1 prior nonVEGF-directed systemic therapy for this disease
  • No concurrent medication that may markedly affect renal function (e.g., vancomycin, amphotericin, ibuprofen, pentamidine)
  • No combination antiretroviral therapy for HIV-positive patients
  • No concurrent hematopoietic growth factors except epoetin alfa and bisphosphonates
  • No concurrent hormones or other chemotherapeutic agents except for steroids given for adrenal failure and hormones administered for nondisease-related conditions (e.g. insulin for diabetes)
  • No concurrent palliative or therapeutic radiation therapy
  • No concurrent drugs or biologics with proarrhythmic potential
  • No other concurrent investigational or commercial agents or therapies to treat the patient's malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00303862

Layout table for location information
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Walter Stadler University of Chicago

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI) Identifier: NCT00303862     History of Changes
Other Study ID Numbers: NCI-2012-02686
NCI-2012-02686 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
14018A ( Other Identifier: University of Chicago )
7111 ( Other Identifier: CTEP )
P30CA014599 ( U.S. NIH Grant/Contract )
N01CM62201 ( U.S. NIH Grant/Contract )
N01CM62209 ( U.S. NIH Grant/Contract )
First Posted: March 17, 2006    Key Record Dates
Results First Posted: November 20, 2013
Last Update Posted: May 21, 2014
Last Verified: January 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Protein Kinase Inhibitors
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Maleic acid
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents